Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | DRD4 | P21917 | 2/20 | 0.40 |
| ▸ | TDO2 | P48775 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | HTR6 | P50406 | 6/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | HTR7 | P34969 | 1/20 | 0.38 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
| ▸ | IDO2 | Q6ZQW0 | 1/20 | 0.38 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17097177 | 0.85 | HTR6 (0.42) | L3MBTL1HTR6HTR2AHTR7 | |
| SCHEMBL17097059 | 0.85 | HTR6 (0.46) | ALDH1A1DRD4TDO2KDM4ETDP1 | |
| SCHEMBL17097267 | 0.84 | HTR6 (0.47) | DRD4HTR6 | |
| SCHEMBL17102146 | 0.83 | IDO1 (0.43) | HTR6HTR2AHTR7IDO1 | |
| SCHEMBL17097196 | 0.83 | TDO2 (0.38) | TDO2HTR6HTR2AHTR7IDO1 | |
| SCHEMBL17097224 | 0.83 | GRIN1 (0.43) | ALDH1A1L3MBTL1DRD4KDM4ETDP1 | |
| SCHEMBL17096725 | 0.82 | HTR6 (0.43) | L3MBTL1HTR6HTR2AHTR7 | |
| SCHEMBL17097305 | 0.82 | KDM4E (0.45) | ALDH1A1KDM4EHTR6HTR2AHTR7 | |
| SCHEMBL17097279 | 0.82 | LMNA (0.41) | TDO2HTR6IDO1IDO2GRM2 | |
| SCHEMBL17097280 | 0.81 | HTR6 (0.41) | L3MBTL1HTR6HTR2AHTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2015140717-A9 | NOVEL 3-INDOL SUBSTITUTED DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE | ITEOS THERAPEUTICS (BE) | 2016-03-24 | — | — | WO | disclosed |
| US-20150266857-A1 | NOVEL 3-INDOL SUBSTITUTED DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE | ITEOS THERAPEUTICS (BE) | 2015-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150266857-A1 | NOVEL 3-INDOL SUBSTITUTED DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE | TDO2, IDO1, IDO2 | HPGD 624/4885ALDH1A1 697/4885HSD17B10 62/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.